Related Experiment Video
Updated: Jun 30, 2025
11:13
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.5K
Berberine chloride suppresses pancreatic adenocarcinoma proliferation and growth by targeting inflammation-related
Lin-Jie Ruan1,2, Ju-Ying Jiao1,2, Chienshan Cheng1,2
1Department of Integrative Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Rd., Xuhui district, Shanghai, China.
Cancer Chemotherapy and Pharmacology
|March 19, 2024
Summary
Berberine (BBR) shows potential in suppressing pancreatic adenocarcinoma (PAAD) by targeting prognostic inflammation-related genes. This study identified key genes and demonstrated BBR
Area of Science:
- Oncology
- Pharmacology
- Bioinformatics
Background:
- Inflammatory crosstalk in the tumor microenvironment drives pancreatic adenocarcinoma (PAAD) progression.
- Berberine (BBR), a natural alkaloid, exhibits anti-inflammatory and antitumor properties, but its mechanism in PAAD is not fully understood.
Purpose of the Study:
- To investigate the effects of Berberine (BBR) on pancreatic adenocarcinoma (PAAD) progression.
- To elucidate the underlying mechanisms of BBR's action in PAAD, focusing on inflammation-related genes.
Main Methods:
- Bioinformatic analysis to identify prognostic inflammation-related genes in PAAD.
- In silico, in vitro, and in vivo studies to assess BBR's pharmacological effects and mechanisms.
- Molecular docking simulations to predict BBR targets.
Main Results:
- Identified 58 prognostic inflammation-related genes in PAAD, forming a predictive model.
- Four candidate genes (CAPS3, PTGS2, ICAM1, CXCR4) were predicted as BBR targets.
- BBR suppressed PAAD cell proliferation, induced cell cycle arrest, and demonstrated tumor-suppressive effects in vivo without significant toxicity.
- BBR downregulated the expression of CAPS3, PTGS2, ICAM1, and CXCR4.
Conclusions:
- Elucidated the prognostic value of inflammation-related genes in PAAD.
- Demonstrated Berberine's (BBR) potential to inhibit PAAD by targeting identified inflammation-related genes.
